Compare 3M Company (MMM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs State Street SPDR S&P Biotech ETF — how do they compare? 3M Company trades at $161.2 (market cap $84.36B), while State Street SPDR S&P Biotech ETF trades at $154.35 (market cap $10.11B). The key difference: 3M Company is far larger — about 8.3× State Street SPDR S&P Biotech ETF's market cap, and 3M Company pays a 1.91% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| MMM | XBI | |
|---|---|---|
Market Cap | $84.36B | $10.11B |
Volume | 2,325,301 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $183.79 | $169.55 |
52-Week Low | $141.10 | $104.99 |
Typical Hold Time | 169 Days | 37 Days |
Enterprise Value | $93.58B | — |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $161.26, down 0.53% with a bearish technical signal despite strong Q2 2026 earnings beats. The company shows robust profitability with 82.77% ROE and 11.9% net margins, though revenue has declined from 2022 peaks. Analyst consensus is mixed with 48% buy ratings and a $191 price target, while recent news highlights operational improvements and litigation management progress.
The outlook balances strong fundamentals against technical weakness and consumer segment challenges. Investment opportunity lies in continued margin expansion and industrial growth, while risks include high debt levels, soft retail demand, and ongoing PFAS litigation costs that could pressure cash flow.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
